List view / Grid view
9 October 2015 | By Victoria White
When using the shRNA in breast cancer cells, Nav1.5 levels were 'knocked down', resulting in reduced tumour growth rates and metastasis...
8 October 2015 | By Victoria White
Researchers have eradicated a specific type of breast cancer tumour in mice by disabling a cancer-causing pathway and administering an immune-molecule based mop-up therapy...
7 October 2015 | By Victoria White
The Cancer Research UK Centres Network Accelerator Award provides infrastructure support to research centres in order to encourage collaboration between different organisations and boost ‘bench to bedside’ science...
5 October 2015 | By Victoria White
Initial studies by Oxford University researchers show that targeting the protein, called PAT4, could restrict cancerous cells' ability to grow...
5 October 2015 | By Victoria White
Rats given RGFP966 were more attuned to what they were hearing and were able to retain and remember more information...
2 October 2015 | By Victoria White
Elevated levels of TGFb may drive the progression of advanced metastatic cancer. As such, it has become an attractive target for cancer drug development...
2 October 2015 | By Victoria White
The technique allows drugs to last longer in the body and attack both primary cancer tumours and the circulating tumour cells...
1 October 2015 | By Victoria White
If further studies show this route can benefit patients, it could help crack one of the toughest challenges in cancer research – how to stop tumours spreading...
30 September 2015 | By Victoria White
Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
30 September 2015 | By Victoria White
The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies...
28 September 2015 | By Victoria White
The newly described Cpf1 system differs in several important ways from Cas9, with significant implications for research and therapeutics...
25 September 2015 | By Victoria White
Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists...
25 September 2015 | By Victoria White
TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
25 September 2015 | By Victoria White
Researchers discovered that FAK inhibition can modulate the balance of immune cells in a tumour enabling an immune response to destroy the cancer cells...
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
